NCT00514306View on ClinicalTrials.gov

Study of Intermittent OSI-906 Dosing

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

July 5, 2007

Primary Completion Date

September 20, 2010

Study Completion Date

September 20, 2010

Conditions
Advanced Solid Tumors
Interventions
DRUG

OSI-906

Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity

Trial Locations (2)

77030

MD Anderson Cancer Center, Houston

SM2 5PT

Drug Development Unit, Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY